The short version
20 companies supply this market — deep enough that no single failure threatens the supply.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Calcium Acetate
Calcium Acetate · CALCIUM ACETATE 667 mg/1 · Capsule · Oral · Amneal Pharmaceuticals of New York LLC
NDC 53746-0590-01 · 100 CAPSULE in 1 BOTTLE · ANDA · View full market →
Medicare Part D
All Part D pricing →Matched to CMS's representative package for this drug (NDC 69097-0862-83) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
ⓘ How this was built
Data sources
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Plans pay at point of saleⓘ
$0.2701per unit
middle half $0.2148–$0.4149 · 1,989 plans · Apr 1, 2026
Est. net of rebatesⓘ
≈ $0.2701
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
36%of plans cover it
tier 3 · prior auth 71% · step therapy 0% · qty limit 15%
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 1 quarter since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for calcium acetate (oral solid) in the next 90 days
OAI inspection at a producing facility (24 months) · sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $71.66 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program · Xywav and Xyrem
Regulatory
- Application
- ANDA201658
- TE code
- —
- Approval date
- Oct 6, 2014
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Calcium Acetate (Capsule)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Amneal Pharmaceuticals of New York LLC | CALCIUM ACETATE 667 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| AvKARE | CALCIUM ACETATE 667 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| AvPAK | CALCIUM ACETATE 667 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Cardinal Health 107, LLC | CALCIUM ACETATE 667 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Chartwell RX, LLC. | CALCIUM ACETATE 667 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Cipla USA Inc., | CALCIUM ACETATE 667 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Exelan Pharmaceuticals, Inc. | CALCIUM ACETATE 667 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | CALCIUM ACETATE 667 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Hikma Pharmaceuticals USA Inc. | CALCIUM ACETATE 667 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Major Pharmaceuticals | CALCIUM ACETATE 667 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| NCS HealthCare of KY, LLC dba Vangard Labs | CALCIUM ACETATE 667 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Nivagen Pharmaceuticals, Inc. | CALCIUM ACETATE 667 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| PD-Rx Pharmaceuticals, Inc. | CALCIUM ACETATE 667 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| PLD Acquisitions LLC DBA Avma Pharma Solutions | CALCIUM ACETATE 667 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Proficient Rx LP | CALCIUM ACETATE 667 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Remedyrepack Inc. | CALCIUM ACETATE 667 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Rising Pharma Holdings, Inc. | CALCIUM ACETATE 667 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Square Pharmaceuticals Limited | CALCIUM ACETATE 667 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Westminster Pharmaceuticals, LLC | CALCIUM ACETATE 667 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| American Health Packaging | CALCIUM ACETATE 667 mg/1 | Jul 15, 2026 | Aug 28, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Calcium Acetate — NDC 53746-0590-01," retrieved September 3, 2026, https://drugdashboards.com/drug/53746059001.
Free to cite with attribution — see how the data is put together.